Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE Attention Turns To Roche's Perjeta After Finally Passing Kadcyla

Executive Summary

After okaying Roche's advanced breast cancer therapy Kadcyla after four years of deliberation, the UK's HTA NICE will now decide how to respond to the Swiss group's proffered patient access scheme for Perjeta.

You may also be interested in...

NICE Reverses View On Perjeta In Breast Cancer After Roche's Price Cut

The UK's HTA NICE says it is now backing Roche's Perjeta (pertuzumab) to treat a certain form of breast cancer on the publicly funded NHS after Roche offered a price discount.

Frustrated Roche Hopes NICE Will Eventually Back Kadcyla

Roche Holding AG hopes the UK's National Institute for Health and Care Excellence will continue seeking possible ways to provide the Swiss drug maker's breast cancer therapy Kadcyla (ado-trastuzumab emtansine) on the publicly-funded National Health Service despite rejecting it in final guidance on cost grounds.

Patient-Centric: Evotec’s CSO Explains R&D Strategy

Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts